AKT1 and gestational diabetes: Remarkably, rFGF4 treatment inhibited inflammation cytokines TNF-α and CD68 and effectively activated p-AMPK, but could not active AKT in HFD induced gestational diabetes mice (Figures 6A, B and Supplemental Figure S1), indicating that it may have no effect on insulin pathway signaling.